BR112018003776A2 - fused heterocyclic compounds as s1p modulators - Google Patents

fused heterocyclic compounds as s1p modulators

Info

Publication number
BR112018003776A2
BR112018003776A2 BR112018003776A BR112018003776A BR112018003776A2 BR 112018003776 A2 BR112018003776 A2 BR 112018003776A2 BR 112018003776 A BR112018003776 A BR 112018003776A BR 112018003776 A BR112018003776 A BR 112018003776A BR 112018003776 A2 BR112018003776 A2 BR 112018003776A2
Authority
BR
Brazil
Prior art keywords
modulators
heterocyclic compounds
fused heterocyclic
compounds
alleviation
Prior art date
Application number
BR112018003776A
Other languages
Portuguese (pt)
Inventor
Hutchins Charles
Van Der Kam Elizabeth
Oellien Frank
Geneste Herve
Van Bergeijk Jeroen
Mezler Mario
Ochse Michael
Walleser Patrick
turner Sean
Lange Udo
Hornberger Wilfried
Amberg Wilhelm
Original Assignee
Abbvie Deutschland
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland, Abbvie Inc filed Critical Abbvie Deutschland
Publication of BR112018003776A2 publication Critical patent/BR112018003776A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção se refere a compostos heterocíclicos como moduladores de s1p, composições farmacêuticas compreendendo tais compostos e suas utilizações no tratamento, alívio ou prevenção de doenças ou distúrbios mediados por um receptor s1p.The invention relates to heterocyclic compounds as s1p modulators, pharmaceutical compositions comprising such compounds and their uses in the treatment, alleviation or prevention of s1p receptor mediated diseases or disorders.

BR112018003776A 2015-08-28 2016-08-26 fused heterocyclic compounds as s1p modulators BR112018003776A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/088447 2015-08-28
US201562242558P 2015-10-16 2015-10-16
PCT/EP2016/070225 WO2017036978A1 (en) 2015-08-28 2016-08-26 Fused heterocyclic compounds as s1p modulators

Publications (1)

Publication Number Publication Date
BR112018003776A2 true BR112018003776A2 (en) 2018-09-25

Family

ID=56801561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003776A BR112018003776A2 (en) 2015-08-28 2016-08-26 fused heterocyclic compounds as s1p modulators

Country Status (10)

Country Link
US (1) US10556907B2 (en)
EP (1) EP3341369A1 (en)
JP (1) JP2018525429A (en)
CN (1) CN108368107B (en)
AU (1) AU2016314973B2 (en)
BR (1) BR112018003776A2 (en)
CA (1) CA2996741A1 (en)
MX (1) MX2018002446A (en)
TW (1) TW201720822A (en)
WO (1) WO2017036978A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234488A1 (en) * 2017-06-23 2018-12-27 Basf Se Substituted cyclopropyl derivatives
WO2020106825A1 (en) * 2018-11-20 2020-05-28 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
WO2021024986A1 (en) * 2019-08-07 2021-02-11 国立大学法人 東京医科歯科大学 Agent for preventing or treating mild cognitive impairment
CN112505213B (en) * 2019-12-19 2022-04-08 金陵药业股份有限公司 Method for detecting components of oral liquid capable of clearing heat, nourishing yin, promoting blood circulation and removing blood stasis
JP7307282B2 (en) * 2020-03-04 2023-07-11 ヒーリオイースト ファーマシューティカル カンパニー リミテッド Benzo 2-azaspiro[4.4]nonane compounds and uses thereof
TW202202495A (en) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 Naphthyridine and pyrido〔3,4-c〕pyridazine derivatives as gamma-aminobutyric acid a receptor subunit alpha 5 receptor modulators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK13532001A3 (en) 1999-04-01 2003-02-04 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
JP4728962B2 (en) * 2003-05-19 2011-07-20 アイアールエム・リミテッド・ライアビリティ・カンパニー Immunosuppressive compounds and compositions
EP1638551B1 (en) * 2003-05-19 2011-12-21 Irm Llc Immunosuppressant compounds and compositions
CN101407471A (en) * 2003-08-29 2009-04-15 小野药品工业株式会社 Compound capable of binding S1P receptor and pharmaceutical use thereof
DE102004020908A1 (en) 2004-04-28 2005-11-17 Grünenthal GmbH Substituted 5,6,7,8-tetrahydropyrido [4,3-d] pyrimidin-2-yl and 5,6,7,8-tetrahydroquinazolin-2-yl compounds
AU2007225273A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
EP2121648A2 (en) * 2007-03-21 2009-11-25 EPIX Pharmaceuticals, Inc. S1p receptor modulating compounds and use thereof
GB0910691D0 (en) * 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
TWI522361B (en) * 2010-07-09 2016-02-21 艾伯維公司 Fused heterocyclic derivatives as s1p modulators
AR084515A1 (en) * 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa NITROGEN HETEROCICLICAL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF DISEASES ASSOCIATED WITH THE CENTRAL NERVOUS SYSTEM SUCH AS PARKINSON AND ALZHEIMER, BETWEEN OTHER
EP2650284A1 (en) * 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
EP3083573A4 (en) * 2013-12-18 2017-08-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Also Published As

Publication number Publication date
AU2016314973A1 (en) 2018-03-08
US20170057966A1 (en) 2017-03-02
JP2018525429A (en) 2018-09-06
CN108368107A (en) 2018-08-03
AU2016314973B2 (en) 2020-10-15
US10556907B2 (en) 2020-02-11
CA2996741A1 (en) 2017-03-09
WO2017036978A1 (en) 2017-03-09
EP3341369A1 (en) 2018-07-04
TW201720822A (en) 2017-06-16
CN108368107B (en) 2021-11-26
MX2018002446A (en) 2019-01-10

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
BR112018003776A2 (en) fused heterocyclic compounds as s1p modulators
PH12018500259A1 (en) Muscarinic agonists
PH12016501570B1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
IL255509B (en) Compounds as ccr2 modulators, pharmaceutical compositions comprising same and their use for the treatment of diseases
EA201791867A1 (en) BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
PH12016501791B1 (en) Muscarinic receptor agonists
CL2016003212A1 (en) Indolin-2-one or pyrrolo-pyridin-2-one derivatives.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
ECSP16078782A (en) ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2018000352A (en) Substituted 4-azaindoles and their use as glun2b receptor modulators.
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EA201890449A1 (en) FUMAGILLINUM HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
BR112016023860A2 (en) heteroaryl substituted heterocyclyl sulfones
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN
MX2020001256A (en) Compounds for the prevention and treatment of medical disorders and uses thereof.
BR112016023926A2 (en) aryl substituted heterocyclyl sulfones
EA201790020A1 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
JO3621B1 (en) Compounds And Compositions As Toll-Like Receptor 7 Agonists
MX2015012393A (en) Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2737 DE 20/06/2023.